Axim Biotechnologies Stock Net Income
| AXIM Stock | USD 0.01 0 26.67% |
As of the 31st of January, Axim Biotechnologies shows the Downside Deviation of 13.49, mean deviation of 9.17, and Risk Adjusted Performance of 0.1043. Axim Biotechnologies technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Axim Biotechnologies information ratio, as well as the relationship between the potential upside and kurtosis to decide if Axim Biotechnologies is priced correctly, providing market reflects its regular price of 0.011 per share. As Axim Biotechnologies appears to be a penny stock we also recommend to validate its total risk alpha numbers.
Axim Biotechnologies' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Axim Biotechnologies' valuation are provided below:Axim Biotechnologies does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Axim |
Axim Biotechnologies 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Axim Biotechnologies' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Axim Biotechnologies.
| 11/02/2025 |
| 01/31/2026 |
If you would invest 0.00 in Axim Biotechnologies on November 2, 2025 and sell it all today you would earn a total of 0.00 from holding Axim Biotechnologies or generate 0.0% return on investment in Axim Biotechnologies over 90 days. Axim Biotechnologies is related to or competes with Zelira Therapeutics, and Sigyn Therapeutics. AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, an... More
Axim Biotechnologies Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Axim Biotechnologies' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Axim Biotechnologies upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 13.49 | |||
| Information Ratio | 0.1262 | |||
| Maximum Drawdown | 76.67 | |||
| Value At Risk | (15.79) | |||
| Potential Upside | 21.43 |
Axim Biotechnologies Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Axim Biotechnologies' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Axim Biotechnologies' standard deviation. In reality, there are many statistical measures that can use Axim Biotechnologies historical prices to predict the future Axim Biotechnologies' volatility.| Risk Adjusted Performance | 0.1043 | |||
| Jensen Alpha | 1.8 | |||
| Total Risk Alpha | 0.811 | |||
| Sortino Ratio | 0.128 | |||
| Treynor Ratio | (3.66) |
Axim Biotechnologies January 31, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1043 | |||
| Market Risk Adjusted Performance | (3.65) | |||
| Mean Deviation | 9.17 | |||
| Semi Deviation | 8.97 | |||
| Downside Deviation | 13.49 | |||
| Coefficient Of Variation | 765.29 | |||
| Standard Deviation | 13.68 | |||
| Variance | 187.21 | |||
| Information Ratio | 0.1262 | |||
| Jensen Alpha | 1.8 | |||
| Total Risk Alpha | 0.811 | |||
| Sortino Ratio | 0.128 | |||
| Treynor Ratio | (3.66) | |||
| Maximum Drawdown | 76.67 | |||
| Value At Risk | (15.79) | |||
| Potential Upside | 21.43 | |||
| Downside Variance | 181.92 | |||
| Semi Variance | 80.47 | |||
| Expected Short fall | (14.95) | |||
| Skewness | 1.37 | |||
| Kurtosis | 4.8 |
Axim Biotechnologies Backtested Returns
Axim Biotechnologies is out of control given 3 months investment horizon. Axim Biotechnologies secures Sharpe Ratio (or Efficiency) of 0.0945, which signifies that the company had a 0.0945 % return per unit of risk over the last 3 months. We were able to collect and analyze data for twenty-seven different technical indicators, which can help you to evaluate if expected returns of 1.34% are justified by taking the suggested risk. Use Axim Biotechnologies Downside Deviation of 13.49, risk adjusted performance of 0.1043, and Mean Deviation of 9.17 to evaluate company specific risk that cannot be diversified away. Axim Biotechnologies holds a performance score of 7 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.49, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Axim Biotechnologies are expected to decrease at a much lower rate. During the bear market, Axim Biotechnologies is likely to outperform the market. Use Axim Biotechnologies total risk alpha and the relationship between the potential upside and period momentum indicator , to analyze future returns on Axim Biotechnologies.
Auto-correlation | -0.37 |
Poor reverse predictability
Axim Biotechnologies has poor reverse predictability. Overlapping area represents the amount of predictability between Axim Biotechnologies time series from 2nd of November 2025 to 17th of December 2025 and 17th of December 2025 to 31st of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Axim Biotechnologies price movement. The serial correlation of -0.37 indicates that just about 37.0% of current Axim Biotechnologies price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.37 | |
| Spearman Rank Test | -0.07 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Axim Biotechnologies reported net income of (16.03 Million). This is 104.7% lower than that of the Biotechnology sector and 122.89% lower than that of the Health Care industry. The net income for all United States stocks is 102.81% higher than that of the company.
Axim Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Axim Biotechnologies' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Axim Biotechnologies could also be used in its relative valuation, which is a method of valuing Axim Biotechnologies by comparing valuation metrics of similar companies.Axim Biotechnologies is currently under evaluation in net income category among its peers.
Axim Fundamentals
| Return On Equity | -100.19 | |||
| Return On Asset | -0.35 | |||
| Operating Margin | (847.86) % | |||
| Current Valuation | 13.6 M | |||
| Shares Outstanding | 186.44 M | |||
| Shares Owned By Insiders | 40.97 % | |||
| Price To Earning | (53.71) X | |||
| Price To Book | 2.86 X | |||
| Price To Sales | 943.93 X | |||
| Revenue | 60.46 K | |||
| Gross Profit | 60.46 K | |||
| EBITDA | (13.42 M) | |||
| Net Income | (16.03 M) | |||
| Cash And Equivalents | 65.16 K | |||
| Total Debt | 5.06 M | |||
| Debt To Equity | 1.36 % | |||
| Current Ratio | 0.06 X | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (2.49 M) | |||
| Earnings Per Share | (0.13) X | |||
| Beta | 1.49 | |||
| Market Capitalization | 4.64 M | |||
| Total Asset | 5.32 M | |||
| Retained Earnings | (36.37 M) | |||
| Working Capital | (1.36 M) | |||
| Current Asset | 1.18 M | |||
| Current Liabilities | 2.55 M | |||
| Z Score | -15.0 | |||
| Net Asset | 5.32 M |
About Axim Biotechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Axim Biotechnologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Axim Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Axim Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in Axim Pink Sheet
Axim Biotechnologies financial ratios help investors to determine whether Axim Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Axim with respect to the benefits of owning Axim Biotechnologies security.